2011
Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins
Querfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan ME, Baron J, Yarosh DB, Foss F, Kuzel TM. Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins. Clinical Cancer Research 2011, 17: 5748-5754. PMID: 21747120, PMCID: PMC3725971, DOI: 10.1158/1078-0432.ccr-11-0556.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingDacarbazineDNA DamageDNA Mismatch RepairFemaleHumansMaleMiddle AgedMutL Protein Homolog 1MutS Homolog 2 ProteinMycosis FungoidesNuclear ProteinsO(6)-Methylguanine-DNA MethyltransferaseSezary SyndromeTemozolomideTreatment OutcomeConceptsMycosis fungoides/Sézary syndromeMulticenter phase II trialPhase II trialMF/SSMethylguanine-DNA methyltransferaseMutL homolog 1II trialSézary syndromeMedian disease-free survivalMismatch repair protein expressionGrade 3 thrombocytopeniaMedian overall survivalDisease-free survivalEfficacy of temozolomideRepair protein expressionProtein expression levelsOral derivativeComplete remissionConstitutional symptomsFrequent toxicitiesGastrointestinal symptomsHematologic toxicityPartial remissionClinical responseOverall survival
2004
Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome
Foss FM. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. Best Practice & Research Clinical Haematology 2004, 17: 573-584. PMID: 15494295, DOI: 10.1016/j.beha.2004.08.009.Peer-Reviewed Original ResearchMeSH KeywordsAntimetabolites, AntineoplasticAntineoplastic Agents, AlkylatingHumansMyelodysplastic SyndromesNucleosidesTopoisomerase I InhibitorsConceptsMyelodysplastic syndromeAnti-vascular endothelial growth factorChemotherapeutic agentsAllogeneic bone marrow transplantationReceptor tyrosine kinase inhibitorsGrowth factorTransplant conditioning regimensBone marrow transplantationTyrosine kinase inhibitorsClonal hematopoietic disordersEndothelial growth factorNovel chemotherapeutic agentsMatrix metalloproteinase inhibitorsFarnesyl transferase inhibitorsIntensive chemotherapyConditioning regimensSupportive careFavorable cytogeneticsPrognostic factorsAntimetabolite therapyMarrow transplantationMDS patientsTreatment paradigmClinical trialsProtein kinase C inhibitor